85 related articles for article (PubMed ID: 19018861)
21. Interferon-alpha for idiopathic myelofibrosis.
Lancet; 1988 Apr; 1(8588):765-6. PubMed ID: 2895289
[No Abstract] [Full Text] [Related]
22. High dose i.v. MP for idiopathic myelofibrosis: a further case.
Ozsoylu S
Eur J Haematol; 1988 Mar; 40(3):282. PubMed ID: 3356246
[No Abstract] [Full Text] [Related]
23. A novel t(1;2)(p33;q33) in secondary postpolycythemic myelofibrosis.
Panani AD
Cancer Genet Cytogenet; 2009 Dec; 195(2):201-2. PubMed ID: 19963128
[No Abstract] [Full Text] [Related]
24. [Use of cyclophosphane in the treatment of myelofibrosis].
Klimova NF; Indosova EN
Probl Gematol Pereliv Krovi; 1971 Jul; 16(7):11-6. PubMed ID: 5124632
[No Abstract] [Full Text] [Related]
25. Idiopathic myelofibrosis associated with dermatomyositis.
Muslimani A; Ahluwalia MS; Palaparty P; Daw HA
Am J Hematol; 2006 Jul; 81(7):559-60. PubMed ID: 16755562
[No Abstract] [Full Text] [Related]
26. Evidence for various 20q status using allelotyping, CGH arrays, and quantitative PCR in distal CIN colon cancers.
Nicolet C; Guérin E; Neuville A; Kerckaert JP; Wicker N; Bergmann E; Brigand C; Kedinger M; Gaub MP; Guenot D
Cancer Lett; 2009 Sep; 282(2):195-204. PubMed ID: 19394760
[TBL] [Abstract][Full Text] [Related]
27. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.
Rossi D; Cerri M; Deambrogi C; Sozzi E; Cresta S; Rasi S; De Paoli L; Spina V; Gattei V; Capello D; Forconi F; Lauria F; Gaidano G
Clin Cancer Res; 2009 Feb; 15(3):995-1004. PubMed ID: 19188171
[TBL] [Abstract][Full Text] [Related]
28. The dawn of targeted therapy for primary myelofibrosis: opportunities and challenges.
Mesa RA
Leuk Res; 2007 Jul; 31(7):883-6. PubMed ID: 17303238
[No Abstract] [Full Text] [Related]
29. Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.
Zheng S; Pan YL; Tao DY; Wang JL; Huang KE
Scand J Gastroenterol; 2009; 44(6):760-3. PubMed ID: 19096980
[TBL] [Abstract][Full Text] [Related]
30. Identification of del(20q) in a subset of patients diagnosed with idiopathic thrombocytopenic purpura.
Soupir CP; Vergilio JA; Kelly E; Dal Cin P; Kuter D; Hasserjian RP
Br J Haematol; 2009 Mar; 144(5):800-2. PubMed ID: 19055669
[No Abstract] [Full Text] [Related]
31. [Correlation between chromosome 13q14 deletion and 1q abnormality in multiple myeloma].
Chen LJ; Li JY; Zhu Y; Wang XW; Qiu HR; Yang RF; Xu W; Xu JR; Lu H
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Feb; 26(1):102-5. PubMed ID: 19199264
[TBL] [Abstract][Full Text] [Related]
32. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma.
Klatte T; Rao PN; de Martino M; LaRochelle J; Shuch B; Zomorodian N; Said J; Kabbinavar FF; Belldegrun AS; Pantuck AJ
J Clin Oncol; 2009 Feb; 27(5):746-53. PubMed ID: 19124809
[TBL] [Abstract][Full Text] [Related]
33. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level.
Huang J; Tefferi A
Eur J Haematol; 2009 Aug; 83(2):154-5. PubMed ID: 19366369
[No Abstract] [Full Text] [Related]
34. Two candidate tumor suppressor genes, MEOX2 and SOSTDC1, identified in a 7p21 homozygous deletion region in a Wilms tumor.
Ohshima J; Haruta M; Arai Y; Kasai F; Fujiwara Y; Ariga T; Okita H; Fukuzawa M; Hata J; Horie H; Kaneko Y
Genes Chromosomes Cancer; 2009 Dec; 48(12):1037-50. PubMed ID: 19760604
[TBL] [Abstract][Full Text] [Related]
35. Myelofibrosis.
Malpas JS
Proc R Soc Med; 1968 May; 61(5):499. PubMed ID: 5655243
[No Abstract] [Full Text] [Related]
36. Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis.
Lee J
Ann Hematol; 2009 Jul; 88(7):699-700. PubMed ID: 19030859
[No Abstract] [Full Text] [Related]
37. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.
Hussein K; Huang J; Lasho T; Pardanani A; Mesa RA; Williamson CM; Ketterling RP; Hanson CA; Van Dyke DL; Tefferi A
Eur J Haematol; 2009 Apr; 82(4):255-9. PubMed ID: 19215287
[TBL] [Abstract][Full Text] [Related]
38. Concomitant t(3;3)(q21;q26), trisomy 19, and E255V mutation associated with imatinib mesylate resistance in chronic myelogenous leukemia.
Park TS; Cheong JW; Kim SJ; Lee KW; Song J; Lee KA; Suh B; Song S; Choi JR
Cancer Genet Cytogenet; 2009 Apr; 190(1):46-8. PubMed ID: 19264234
[No Abstract] [Full Text] [Related]
39. Chromosomal deletion unmasking a recessive disease: 22q13 deletion syndrome and metachromatic leukodystrophy.
Bisgaard AM; Kirchhoff M; Nielsen JE; Kibaek M; Lund A; Schwartz M; Christensen E
Clin Genet; 2009 Feb; 75(2):175-9. PubMed ID: 19054018
[TBL] [Abstract][Full Text] [Related]
40. Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients.
Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Saumell S; Salar A; Abella E; Gimeno E; Serrano S; Florensa L; Sánchez B; Pedro C; Besses C
Br J Haematol; 2009 Sep; 146(5):504-9. PubMed ID: 19604233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
